Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | TETON: azenosertib, an oral WEE-1 inhibitor, in uterine serous tumors

Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center & GOG-F, Houston, TX, discusses the investigation of azenosertib, an oral WEE-1 inhibitor, in patients with uterine serous tumors driven by p53 mutations in the TETON (NCT04814108) trial. Although initial results showed promising response rates, the overall response rate decreased when the study was expanded, suggesting that patient selection may not have been optimal. As a result, further research is needed to identify specific biomarkers, such as CCNE1, to better select patients who may benefit from this treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Azenosertib is an oral Wee-1 inhibitor, and we had a lot of reason to believe that this would be a synthetic lethality situation in patients with uterine serous tumors because they’re driven by a p53 mutation. And we know when we have a p53 mutation, we become very dependent on the checkpoint that is guarded by Wee-1. And so if you’ve knocked out P53 and then you knock out Wee-1, you can see that synthetic lethality and basically cell kill of the tumor specifically...

Azenosertib is an oral Wee-1 inhibitor, and we had a lot of reason to believe that this would be a synthetic lethality situation in patients with uterine serous tumors because they’re driven by a p53 mutation. And we know when we have a p53 mutation, we become very dependent on the checkpoint that is guarded by Wee-1. And so if you’ve knocked out P53 and then you knock out Wee-1, you can see that synthetic lethality and basically cell kill of the tumor specifically. So that was kind of the rationale behind the study. During the study, we examined a number of different dose levels for Azenosertib, trying to get to the ideal amount of tolerability. The main side effect we see is nausea, and ultimately ended up on a five-day on, two-day off schedule that works quite well. And that’s the schedule that’s being explored in other tumor types like ovarian cancer. Early parts of the study, when we looked at uterine serous, had very high levels of response rate, 30, 40 percent, you know, out of just a small number of patients. Unfortunately, when we expanded it to a larger group of patients and adjusted the dose, we saw that that response rate fall down and it only hit about a 16 percent response rate. So this isn’t something that we’re moving forward. But I think a lot of it has to do with we just didn’t select the patients appropriately. We know now that a P53 mutation is not enough to sensitize to Wee-1. So doing more specific focus around CCNE1 and other things is going to be helpful in the development of this drug.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.